The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.

Vergari, A., Cortegiani, A., Rispoli, M., Coluzzi, F., Deni, F., Leykin, Y., et al. (2020). Sufentanil Sublingual Tablet System: from rationale of use to clinical practice. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 24(22), 11891-11899 [10.26355/eurrev_202011_23847].

Sufentanil Sublingual Tablet System: from rationale of use to clinical practice

Cortegiani, A;Giarratano, A;
2020

Abstract

The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.
Vergari, A., Cortegiani, A., Rispoli, M., Coluzzi, F., Deni, F., Leykin, Y., et al. (2020). Sufentanil Sublingual Tablet System: from rationale of use to clinical practice. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 24(22), 11891-11899 [10.26355/eurrev_202011_23847].
File in questo prodotto:
File Dimensione Formato  
11891-11899.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 444.5 kB
Formato Adobe PDF
444.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/469403
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact